Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TH-SC01 for complex perianal fistula
NCT05677672Phase 2Unknown
- Sponsor
- Jiangsu Tuohong Kangheng Pharmaceutical Co., Ltd.
- Start
- Dec 2022
- Primary completion
- Aug 2023
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TH-SC01 in perianal fistula (2 arms), sponsored by Jiangsu Tuohong Kangheng Pharmaceutical Co., Ltd. Primary endpoints: Severity and incidence of study drug-related adverse-events at Day 28, Dose-limiting toxicity at Day 28 and 2 more. Status: unknown.
02
Drugs
TH-SC01
03
Conditions
perianal fistula
Beyond the preview
Go deeper on NCT05677672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05677672.